An epidemiological study to confirm the prevalence of HER2 amplification in solid tumor in Japan using C-CAT database

An epidemiological study to confirm the prevalence of HER2 amplification in solid tumor in Japan using C-CAT database - An epidemiological study to confirm the prevalence of HER2 amplification in solid tumor in Japan using C-CAT database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057382

Enrollment

90000

Registered

2025-03-31

Start date

2025-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all the following conditions will be included. 1) patients registered in C-CAT data base for the period from June 1, 2019, to December 31, 2024 2) Patients with solid tumors

Exclusion criteria

Exclusion criteria: Patients who meet any of the following conditions will be excluded. 1) Patients whose "previous registration" is "Yes" or "Unknown" 2) Patients whose CGP test results were not analyzed

Design outcomes

Primary

Measure	Time frame
Prevalence of HER2 amplification (overall and each tumor type) Background information, genetic alterations, Status of the treatment after Expert Panel, breakdown	—

Countries

Japan

Contacts

Public ContactDaiichi Sankyo Contact for JP-MA Clinical Study Information

Daiichi Sankyo Co., Ltd. Oncology Medical Science Department I

contact_for_DSMA_JP@daiichisankyo.com03-6225-1111

Outcome results